KSHV infection skews macrophage polarisation towards M2-like/TAM and activates Ire1 α-XBP1 axis up-regulating pro-tumorigenic cytokine release and PD-L1 expression

Maria Saveria Gilardini Montani1, Luca Falcinelli1, Roberta Santarelli1, Marisa Granato1, Maria Anele Romeo1, Nives Cecere1, Roberta Gonnella1, Gabriella D’Orazio2,3, Alberto Faggioni1 and Mara Cirone1

BACKGROUND: Kaposi’s Sarcoma Herpesvirus (KSHV) is a gammaherpesvirus strongly linked to human cancer. The virus is also able to induce immune suppression, effect that contributes to onset/progression of the viral-associated malignancies. As KSHV may infect macrophages and these cells abundantly infiltrate Kaposi’s sarcoma lesions, in this study we investigated whether KSHV-infection could affect macrophage polarisation to promote tumorigenesis.

METHODS: FACS analysis was used to detect macrophage markers and PD-L1 expression. KSHV infection and the molecular pathways activated were investigated by western blot analysis and by qRT-PCR while cytokine release was assessed by Multi-analyte Kit.

RESULTS: We found that KSHV infection reduced macrophage survival and skewed their polarisation towards M2 like/TAM cells, based on the expression of CD163, on the activation of STAT3 and STAT6 pathways and the release of pro-tumorigenic cytokines such as IL-10, VEGF, IL-6 and IL-8. We also found that KSHV triggered Ire1 α-XBP1 axis activation in infected macrophages to increase the release of pro-tumorigenic cytokines and to up-regulate PD-L1 surface expression.

CONCLUSIONS: The findings that KSHV infection of macrophages skews their polarisation towards M2/TAM and that activate Ire1 α-XBP1 to increase the release of pro-tumorigenic cytokines and the expression of PD-L1, suggest that manipulation of UPR could be exploited to prevent or improve the treatment of KSHV-associated malignancies.

© The Author(s), under exclusive licence to Cancer Research UK 2020

Published online: 18 May 2020

Received: 18 September 2019 Revised: 27 February 2020 Accepted: 15 April 2020

1Department of Experimental Medicine, Sapienza University of Rome, laboratory affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Rome, Italy; 2Department of Research, Advanced Diagnostics, and Technological Innovation, Regina Elena National Cancer Institute, Rome, Italy and 3Department of Medical, Oral and Biotechnological Sciences, University “G. D’Annunzio”, 66100 Chieti, Italy

Correspondence: Mara Cirone (mara.cirone@uniroma1.it)
produce the large amount of proteins required for viral replication. Moreover, in the course of microbial infection, UPR could be, independently of ER stress, activated by the pattern recognition receptor (PRR) signalling. It is known that UPR, depending on the intensity and duration of ER stress may up-regulate pro-survival molecules such as binding immunoglobulin protein (BIP), promoting the adaption to cell stress, or increase the expression of pro-death molecules such as C/EBP homologous protein (CHOP). However, UPR may affect several cellular processes, i.e. it may affect immune response even if the consequences of the activation of the different UPR arms on immune cell function has just begun to be investigated. For example it has been observed that ATF4 and CHOP up-regulation, that mainly occurs downstream of PERK, occurred in myeloid-derived suppressor cells (MDSCs) present in the tumour environment. Therefore, in this study we next investigated whether KSHV infection could activate Ire1α and PERK branches of UPR in macrophages and if this effect increases the release of cytokines promoting tumorigenesis. Finally the expression of programmed death-ligand 1 (PD-L1), an immune check point inhibitor whose promoting tumorigenesis and to occur in KSHV-infected monocytes,25 was evaluated in KSHV-infected macrophages and correlated with Ire1α and PERK activation. Unveiling the molecular mechanisms through which KSHV dysregulates the immune response could allow specific targeting of molecules promoting KSHV-associated malignancies.

**METHODS**

Monocytes isolated, macrophage differentiation and KSHV infection

Monocytes isolated from human peripheral blood mononuclear cells (PBMCs) of healthy donors as previously described were cultured in RPMI 1640 (Euroclone, ECH9006L) containing 10% FCS, 2 mM l-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin (complete medium) with the addition of 50 ng/ml recombinant human macrophage-colony stimulating factor M-CSF (Peprotech, 300-25) every two days for 6/7 days to differentiate in macrophages. Macrophages were infected with KSHV, obtained as previously described, at a multiplicity of infection (MOI) of 10 genome equivalents/cell for 1 h at 37 °C, or mock-infected and then cultured for additional 24 h in 10% foetal calf serum (FCS) RPMI 1640 medium. In some experiments, macrophages were left untreated (M0) or polarised towards M1 or M2 macrophages by LPS and IFN gamma (100 ng/ml and 20 ng/ml) or IL-4 (25 ng/ml), respectively, added for 24 h.

HUVECs cells cultured in endothelial cell growth medium (EBM, CC-3121, Lonza) containing EGM SingleQuots (CC-4133), were KSHV-infected or mock-infected for 2 h at 37 °C and then plated in complete medium supplemented or not with 0.22 μm filtered supernatant of KSHV-infected, or UV-KSHV treated macrophages for 96 h. UV-KSHV inactivation was carried out at 1500 mJ in a cross-linker for 10 min (Spectrolinker XL-1500 UV crosslinker).

RNA isolation and quantitative real-time PCR analysis

Total RNA was extracted from cells by using TRizReagent (Invitrogen, Carlsbad, CA, USA) in accordance with manufacturer’s instructions. PCR analyses were carried out using the following specific oligonucleotides:

- LANa forw CCAGAGCTAAGAGTCTGTTG- LANa rev GCAGTCTCCAGAGTCTTCTC
- ORF50forwCACAAAAATGGCGCAAGATGTA- ORF50revTGTTAGAGTTGGCTTTCCAGTT
- K8.1forw TAAACGGGACCAGTACTGCAGC- K8.1rev GTTTTCTGCGACCGGTGATACG
- ACTfoiwTCACCACCATGTCGATCAGTTACT- Actrev CAGCGGAAAAGCTATGGCCAAAT

After 24 h of KSHV infection, a trypan blue (Euroclone) exclusion assay was performed to assess cell viability of uninfected (mock) or KSHV-infected macrophages. Live cells were counted by light microscopy using a Neubauer haemocytometer. The experiments were performed in triplicate and repeated at least three times.

Immunofluorescence staining and FACS analysis

After 24 h, uninfected, KSHV-infected or UV-KSHV treated macrophages were stained with antibodies against CD86 (Miltenyi Biotec, 130-094-877), CD163 (Santa Cruz Biotechnology, sc20066), PD-L1 (Biolegend, 329706) and isotype control antibody (Miltenyi Biotec, 130-095-897) and analysed by FACS Calibur flow cytometer (BD Transduction Laboratories), using CELLQuest software (BD Biosciences). Debris and dead cells were excluded from the analysis, gating live cells in a forward versus side scatter (FSC vs SSC) density plot. For each analysis 10,000 events were recorded.

Western blot analysis

In all, 1 × 10^6 uninfected or KSHV-infected cells were lysed, subjected to electrophoresis and transferred to nitrocellulose membranes, as previously described. Membranes were blocked in PBS-0.1% Tween 20 solution containing 3% BSA, probed with specific antibodies and developed using ECL Blotting Substrate (Advansta). The following antibodies were used: mouse monoclonal antibody against Kb-ZIP (Santa Cruz Biotechnology, sc-69797), pSTAT6 (1:100; Santa Cruz Biotechnology Inc., sc-136019), STAT6 (1:100; Santa Cruz Biotechnology Inc., sc-136019), mouse monoclonal anti-STAT3 (1:1000; BD Transduction Laboratories, 610189), mouse monoclonal anti-phospho-STAT3 (p-Tyr705, 1:100; Santa Cruz Biotechnology Inc., sc-8059), pSTAT1 (1:100; Santa Cruz Biotechnology Inc., sc-136229), STAT1 (1:100; Santa Cruz Biotechnology Inc., sc-464), mouse monoclonal anti-Ire1α (1:100; Santa Cruz Biotechnology, sc-390690), XBP1s (NovusBio NBP1-776815S), ATF4 (R&D system, MA87218), rabbit polyclonal anti-BIP (1:100; Cell Signaling, 3177), mouse monoclonal anti-CHOP (1:100; Santa Cruz Biotechnology, sc-7351), and anti-β-actin (1:10000; Sigma Aldrich, A5441). Goat anti-mouse IgG-HRP and anti-rabbit IgG-HRP (1:10000 Santa Cruz Biotechnology Inc) were used as secondary antibodies.

Chloriminescent immunometric assay

After 24 hs of culture, supernatants from 48h- and GSX 2606414-pretreated or not KSHV-infected and mock control macrophages were collected and Interleukin-10 (IL-10), vascular endothelial growth factor (VEGF), Interleukin-8 (IL-8), Interleukin-6 (IL-6) and interferon gamma (IFN-γ) were measured by Magnetic Luminex assay performed by R&D systems a Bio-Techne brand, using a human pre-mixed multi-analyte kit (R&D systems Bio-Techne, LXSAHM) according to the manufacturer's instructions.
Densitometric analysis
The quantification of proteins bands was performed by densitometric analysis using the Image J software, which was downloaded from NIH website (http://imagej.nih.gov).

Statistical analysis
Data are represented by the mean ± standard deviation (SD) of at least three independent experiments and two-tailed Student's t-test was used for statistical significance of the differences.
between treatment groups. Difference was considered statistically significant when $p$-value was ≤ 0.05.

RESULTS
KSHV infection reduces the survival of macrophages and skews their phenotype towards M2-like/TAM profile

Human primary CD14-positive monocytes, isolated from healthy donors and differentiated into macrophages after 6 days of exposure to M-CSF, were infected by KSHV, as previously described. After 24 h, viral infection was demonstrated by detecting the expression of the KSHV early lytic antigen K-bZIP by western blot (Fig. 1a) and by IFA (Fig. 1b) and by qRT-PCR assessing the expression of latent, early lytic and late lytic antigens, LANA, ORF50 and K8.1, respectively (Fig. 1c). We then observed that viral infection reduced the survival of macrophages (Fig. 1d) and investigated whether it could also affect their polarisation, as macrophages are in a dynamic state of activation that ranges from the classically activated M1 to a group of alternatively activated cells called M2. As suggested by cell morphology (Fig. 1e) and by the expression of surface markers (Figs. 1f, g), KSHV skewed macrophages polarisation towards M2-like/TAM profile. Indeed these cells similarly to M2 displayed a more elongated phenotype and up-regulated the expression of CD163, while slightly affected CD86 expression. CD86 and CD163 are molecules expressed mainly by M1 macrophages treated with LPS/IFN gamma or by M2 macrophages exposed to IL-4, respectively. UV-inactivated KSHV was not able to alter macrophage phenotype, suggesting that infection was required to induce the above-described effects (Fig. 1e–g). One of the most important features through which macrophages shape immune response is through the release of cytokines, therefore we next evaluated their production by mock- and KSHV-infected macrophages. As shown in Fig. 2a, viral infection increased the released of pro-tumorigenic cytokines including the immune suppressive IL-10 and VEGF and the pro-inflammatory cytokines IL-6 and IL-8. Interestingly, VEGF and IL-8 are known to exert also a strong pro-angiogenetic effect and contribute to the pathogenesis of

![Image](image-url)

**Fig. 2** KSHV infection promotes the release of pro-tumorigenic cytokines. a IL-10, VEGF, IL-8, IL-6 and IFN-$\gamma$ released by KSHV- and mock-infected macrophages were measured by Luminex assay. Mean plus SD of three different experiments is reported. *$p$-value < 0.05; b Morphology of KSHV-infected HUVEC plus supernatant of KSHV-infected macrophages (sup KSHV-MΦ), KSHV-infected HUVEC, Mock HUVEC, Mock HUVEC treated with supernatant of KSHV-infected macrophages (sup KSHV-MΦ) or treated with supernatant of UV-KSHV-exposed macrophages (sup UV-KSHV-MΦ) was observed utilising an optical microscope ($\times$40 magnification); c Snail expression in mock-, KSHV-infected and KSHV-infected HUVEC plus sup KSHV-MΦ was evaluated by western blot analysis. $\beta$-actin ($\beta$-ACT) was used as loading control. A representative experiment out of three is shown. Histograms represent the mean plus S.D. of the densitometric analysis of the ratio of snail/$\beta$-actin. *$p$-value < 0.05.
On the other hand, we found that KSHV did not increase the production of IFN-γ, cytokine that when released by macrophages can act in an autocrine fashion and stimulate their killing activity. These results suggest that the KSHV infection altered the pattern of cytokine secretion by macrophages, increasing the release of immune suppressive and pro-tumorigenic cytokines. To verify that the cytokines released by infected macrophages could effectively promote viral-driven tumorigenesis, we evaluated the effect of supernatants derived from infected macrophages in the process of KSHV-mediated transformation of HUVEC cells into spindle cells that resemble Kaposi’s Sarcoma cells. We found that HUVEC acquired a stronger spindle-like phenotype in the presence of supernatant of KSHV-infected macrophages and expressed higher level of snail, a typical endothelial to mesenchymal transition marker, whose expression is known to increase in these cells following KSHV infection. When the supernatants from KSHV-infected macrophages or from UV-virus-exposed macrophages were used to treat uninfected HUVEC, we found that their morphology was only slightly affected, suggesting that the factors released by KSHV-infected macrophages were able to contribute to the virus-induced transformation in spindle cells rather than alter per se the HUVEC phenotype.

KSHV infection activates STAT3 and to a lesser extent STAT6 in macrophages while slightly affects STAT1 phosphorylation. We investigated whether KSHV-induced M2-like/TAM polarisation could correlate with the activation of the molecular pathways usually activated in M2-like/TAM cells. We found that viral infection increased the phosphorylation of STAT3 and to a lesser extent of STAT6, molecules activated in M2 polarised macrophages (Fig. 3a, b). Conversely STAT1, phosphorylated in M1-polarised macrophages exposed to LPS plus IFN-γ, was almost unaffected by KSHV-infection (Fig. 3c). These results indicate that the virus was able to phosphorylate somehow the molecular pathways typically activated in M2-polarised macrophages.

KSHV activates UPR and up-regulates PD-L1 on the surface of infected macrophages. STAT3 and STAT6 have been reported to activate Ire1α arm of UPR and viral infection may trigger UPR by inducing ER stress or even by engaging the PRRs. Therefore, we next investigated whether KSHV could activate UPR in infected macrophages and found that the expression of Ire1α and its target XBP1s as well as ATF4 increased, suggesting that Ire1α and PERK branches of UPR were activated. In correlation with the activation of these sensors, an up-regulation of BIP and CHOP, the pro-survival and pro-death molecules of UPR, was also observed (Fig. 4a, b). As UPR triggering has been reported to up-regulate the expression of the immune checkpoint inhibitor PD-L1, we next evaluated whether KSHV could do so in infected macrophages. As shown in Fig. 4c, d, FACS analysis indicated that the expression of PD-L1 increased in KSHV-infected cells in comparison to mock-infected control, effect that may strongly contribute to the impairment of immune response.
The inhibition of Ire1α endoribonuclease activity counteracts the release of pro-tumorigenic cytokines and PD-L1 up-regulation induced by KSHV-infection. UPR activation may influence the cytokine release by macrophages, therefore here we next investigated the role of Ire1α and PERK activation on the production of cytokines by KSHV-infected macrophages. At this aim, we pre-treated macrophages with 4μ8C Ire1α endoribonuclease inhibitor or with GSK 2606414 (GSK) PERK inhibitor before viral infection. We observed that the release of either the immune suppressive IL-10 and VEGF and the pro-inflammatory cytokines IL-6 and IL-8 was reduced by 4μ8C while GSK only reduced IL-6 production (Fig. 5a). Finally, we found that PD-L1 surface expression was reduced by 4μ8C pre-treatment while it was slightly influenced by GSK (Fig. 5b, e). These results suggest that Ire1 α-XBP1 axis targeting could be preferentially exploited to counteract several aspects of KSHV-driven immune dysfunction and tumorigenesis. We finally assessed that such inhibitors did not interfere with KSHV infection (Fig. 5d) and evaluated whether GSK, although not able to counteract PD-L1 expression, could efficiently reduce ATF4 expression that mainly occurs downstream of PERK activation (Fig. 5e).

**DISCUSSION**

In this study, we show for the first time that KSHV infection phosphorylated STAT3 and to a lesser extent STAT6 pathways in human primary macrophages and skewed their polarisation towards M2-like/TAM profile. According to previous findings showing that STAT3 and STAT6 transcription factors activated the Ire1 α-XBP1 axis, here we found that the expression of spliced XBP1 (XBP1s) increased following KSHV infection. However, ATF4, CHOP and BIP were also up-regulated, suggesting that a more general ER stress/UPR was activated by viral infection in macrophages. Previous studies have indicated that UPR could regulate the function of immune myeloid cells such DCs and macrophages. It has been also reported that elevated UPR activation promoted M2-like polarisation of macrophages and foam cell formation or that the treatment with LPS, that induced M1 polarisation, could reduce GRP78/BIP and PERK expression. Furthermore, BIP up-regulation has been correlated with fatty acid oxidation that may occur in M2 polarised macrophages. In the last years, attention has been focused on the impact of UPR on the cytokine release by immune cells, as UPR may influence their production by activating PRR signalling or the cytokine transcription factors. Interestingly in this study, we found that Ire1 α-XBP1 axis activation by KSHV in M2/TAM polarised macrophages promoted the release of immunosuppressive as well as pro-inflammatory cytokines, while PERK activation was involved only in IL-6 production. KSHV infection of macrophages indeed increased the release of cytokines such as VEGF and IL-8, that, besides inducing immune suppression, promote angiogenesis and may sustain tumour growth. These cytokines, together with IL-10 and IL-6, whose release also increased following KSHV infection, play an essential role in the pathogenesis of virus-associated malignancies. Thus, it is possible that macrophages could be infected also in vivo by KSHV, especially within the tumour microenvironment, and the infected cells could then strongly contribute to the onset and survival of virus-associated malignancies. In support of this hypothesis, here we showed that...
Fig. 5 The Ire1α/XBP1 axis interferes with the pro-tumorigenic cytokines release and PD-L1 expression of KSHV-infected macrophages. 
a IL-10, VEGF, IL-8, IL-6 and IFN-γ released by mock-, KSHV-infected macrophages and 4μ8c- (Ire1α inhibitor) or GSK 2606414 (GSK)- (PERK inhibitor) pre-treated KSHV-infected macrophages were measured by Luminex assay. Mean plus SD of three different experiments is reported. *p-value < 0.05; b and c PD-L1 expression on mock-, KSHV-infected macrophages and 4μ8c or GSK 2606414 (GSK)- pre-treated KSHV-infected macrophages was evaluated by FACS analysis. Grey peaks represent the isotype controls. Histograms representing the mean plus SD of PD-L1 MFI (Mean fluorescence intensity) are reported. *p-value < 0.05 and a representative experiment is shown, and the mean of fluorescence intensity is indicated; d expression of K-bZIP in untreated or 4μ8c or GSK 2606414 (GSK)- pre-treated KSHV-infected macrophages; e ATF4 expression in mock-, KSHV-infected and GSK 2606414 (GSK)-pre-treated KSHV-infected macrophages was evaluated by western blot analysis. β-actin (β-ACT) was used as loading control. A representative experiment out of three is shown. Histograms represent the mean plus S.D. of the densitometric analysis of the ratio of each protein/ β-ACT. *p-value < 0.05.
the supernatants of virus-infected macrophages promoted KSHV-driven transformation of HUVEC into spindle cells. This result, together with previous findings showing that KSHV-infected HUVEC release factors that promoted macrophages polarisation into TAM, suggests that an active cross-talk between viral-infected HUVEC and viral-infected macrophages may occur in vivo, within the tumour bed of KS lesions. Indeed, most of the cytokines released by KSHV-infected macrophages can act in an autocrine and paracrine fashion and activate both in immune and tumour cells transcription factors such as STAT3 that plays a dual role, impairing the function of immune cells and concomitantly sustaining the growth of tumour cells.45,46 Of note, the interplay between STAT3 and Ire1α has been previously reported as STAT3, together with STAT6, may activate Ire1α endoribonuclease activity36 and Ire1α may in turn contribute to STAT3 phosphorylation.47 Among the numerous targets of STAT3 there is α-ENaC, whose expression has been reported to increase in macrophages undergoing ER stress,39 and PD-L1,48 molecules found to be up-regulated on the surface of KSHV-infected macrophages. The increase of PD-L1 that may strongly contribute to viral-induced immune suppression,49 has been previously reported to be up-regulated by KSHV52 as well as by EBV infection in monocytes,50 suggesting that such effect may represent a common strategy used by gammaherpesvirus to impair T cell function.

In conclusions, in this study, we identified that UPR activation, particularly the Ire1α arm, was a key mechanism leading to PD-L1 up-regulation and to the release of pro-tumorigenic cytokines induced by KSHV in M2/TAM polarised macrophages. UPR manipulation could thus allow to re-shape infected-macrophages into a less pro-tumorigenic profile, considering that plasticity is an intriguing characteristic of these cells that are able to shift back and forth between the M1 and M2/TAM extremes, depending on the different environmental conditions to which they are subjected.50 This study suggests that UPR manipulation could be a promising approach to counteract the pro-tumorigenic activity of M2/TAM macrophages, besides improving the outcome of several cytotoxic anti-cancer treatments.

ACKNOWLEDGEMENTS
We thank Dr. G. Grelli (Blood bank, Sapienza University of Rome) and Dr G. Mandarelo and Dr R. Gasbarri (Immunohematology and Transfusion Service, Bellcote Hospital, Viterbo) for providing buffy coats. We also thank Alessia Garufi and Micol Di Segni for technical assistance in qRT-PCR experiments.

AUTHOR CONTRIBUTIONS
M.S.G.M. performed macrophage preparation and FACS analysis. L.F., R.S., M.C., and M.S.G.M. performed cell culture and Elisa assays. G.D.O. carried out qRT-PCR. M.C., G.D.O. and M.S.G.M. performed macrophage preparation and FACS analysis. L.F., R.S., N.C., M.S.G.M. and Dr R. Gasbarri (Immunohematology and Transfusion Service, Bellcote Hospital, Viterbo) for providing buffy coats. We also thank Alessia Garufi and Micol Di Segni for technical assistance in qRT-PCR experiments.

ADDITIONAL INFORMATION
Ethics approval and consent to participate This research involving human subjects has been performed in accordance with the Declaration of Helsinki and has been approved by the ethic committee of Policlinico Umberto I, Rome, Italy (847/19).

Data availability The datasets generated and/or analysed during the current study are available from the corresponding author upon reasonable request.

Competing interests The authors declare no competing interests.

Funding information This work was supported by grants from Istituto Pasteur Italia-Fondazione Cenci Bolognetti, PRIN 2017 (2017K5SHLC) and by the Italian Association for Cancer Research (AIRC) Grant (IG 2019 ld.23040).

KSHV infection skews macrophage polarisation towards M2-like/TAM and... MS Gilardini Montani et al.

Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

REFERENCES
1. Dittmer, D. P. & Damania, B. Kaposi sarcoma-associated herpesvirus: immunobiology, oncogenesis, and therapy. J. Clin. Invest. 126, 3165–3176 (2016).
2. Cirone, M., Lucania, G., Bergamo, P., Trivedi, P., Frati, L. & Faggioni, A. Human herpesvirus 8 (HHV-8) inhibits monocyte differentiation into dendritic cells and impairs their immunostimulatory activity. Immunol. Lett. 113, 40–46 (2007).
3. Santarelli, R., Granato, M., Bellas, M., Lotti, L. V., Conte, V., Trivedi, P., Santarelli, R. et al. Activation of dendritic cells by tumor cell death. Oncoimmunology 1, 1218–1219 (2012).
4. Giardini Montani, M. S., Falcinelli, L., Santarelli, R., Romeo, M. A., Granato, M., Faggioni, A. et al. Kaposi Sarcoma Herpes Virus (KSHV) infection inhibits macrophage formation and survival by counteracting Macrophage Colony-Stimulating Factor (M-CSF)-induced increase of Reactive Oxygen Species (ROS), c-Jun N-terminal kinase (JNK) phosphorylation and autophagy. Int J. Biochem Cell Biol. 114, 105560 (2019).
5. Santarelli, R., Bonnella, R., Di Giovenale, G., Lotti, L. V., Capobianchi, A., Granato, M. et al. STAT3 activation by KSHV correlates with IL-10, IL-6 and IL-23 release and an autophagic block in dendritic cells. Sci. Rep. 4, 4241 (2014).
6. Bhaskaran, N., Ghosh, S. K., Yu, X., Qin, S., Weinberg, A., Pandiyan, P. et al. Kaposi’s sarcoma-associated herpesvirus infection promotes differentiation and polarization of monocytes into tumor-associated macrophages. Cell Cycle 16, 1611–1621 (2017).
7. Mantovani, A., Sica, A., Sozzani, S., Allavena, P., Vecchi, A. & Locati, M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 25, 677–686 (2004).
8. Yang, L. & Zhang, Y. Tumor-associated macrophages: from basic research to clinical application. J. Hematol. Oncol. 10, 58 (2017).
9. Olson, O. C. & Joyce, J. A. Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response. Nat. Rev. Cancer 15, 712–729 (2015).
10. Gregory, S. M., Wang, L., West, J. A., Dittmer, D. P. & Damania, B. Latent Kaposi’s sarcoma-associated herpesvirus infection of monocytes downregulates expression of adaptive immune response costimulatory receptors and proinflammatory cytokines. J. Virol. 86, 3916–3923 (2012).
11. Wang, C., Zhu, C., Wei, F., Zhang, L., Mo, X., Feng, Y. et al. Constitutive activation of interleukin-13/STAT6 contributes to Kaposi’s sarcoma-associated herpesvirus-related primary effusion lymphoma cell proliferation and survival. J. Virol. 89, 10416–10426 (2015).
12. Cheng, Z., Zhang, D., Gong, B., Wang, P. & Liu, F. CD163 as a novel target gene of STAT3 is a potential therapeutic target for gastric cancer. Oncotarget 8, 10344–10362 (2017).
13. Gong, M., Zuo, X. & Ma, A. STAT6 upregulation promotes M2 phenotype polarization to suppress atherosclerosis. Med Sci. Monit. Basic Res. 23, 240–249 (2017).
14. Rajal, O. M., Wolfe, A. R., Mandal, P. K., Larson, R., Tin, S., Jimenez, C. et al. Blocking Interleukin (IL)-4 and IL-13-mediated phosphorylation of STAT6 (Y641) decreases M2 polarization of macrophages and protects against macrophage-mediated radioreistance of inflammatory breast cancer. Int J. Radiat. Oncol. Biol. Phys. 100, 1034–1043 (2018).
15. Yan, D., Wang, H. W., Bowman, R. L. & Joyce, J. A. STAT3 and STAT6 signaling pathways synergize to promote cathepsin secretion from macrophages via IRE1alpha activation. Cell Rep. 16, 2914–2927 (2016).
16. Zhang, L. & Wang, A. Virus-induced ER stress and the unfolded protein response. Front. Plant Sci. 3, 293 (2012).
17. Smith, J. A. Regulation of cytokine production by the unfolded protein response: implications for infection and autoimmunity. Front. Immunol. 9, 422 (2018).
18. Corazzari, M., Gagliardi, M., Fimia, G. M. & Piacentini, M. Endoplasmic reticulum stress, unfolded protein response, and cancer cell fate. Front Oncol. 7, 78 (2017).
19. Condamine, T., Kumar, V., Ramachandran, I. R., Youn, J. I., Celis, E., Finnegren, N. et al. ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis. J. Clin. Invest. 124, 2626–2639 (2014).
20. Osorio, F., Tavernier, S. J., Hoffmann, E., Saeyes, Y., Martens, L., Vetters, J. et al. The unfolded-protein-response sensor IRE1alpha regulates the function of CD8alpha+ dendritic cells. Nat. Immunol. 15, 248–257 (2014).
KSHV infection skews macrophage polarisation towards M2-like/TAM and... 

MS Gilardini Montani et al.

22. Cubillos-Ruiz, J. R., Silberman, P. C., Rutkowski, M. R., Chopra, S., Perales-Puchalt, A., Song, M. et al. ER stress sensor XBP1 controls anti-tumor immunity by disrupting dendritic cell homeostasis. Cell 161, 1527–1538 (2015).

23. Martinon, F., Chen, X., Lee, A. H. & Glimcher, L. H. TLR activation of the transcription factor XBP1 regulates innate immune responses in macrophages. Nat. Immunol. 11, 411–418 (2010).

24. Chang, L. C., Chen, T. P., Kuo, W. K. & Hua, C. C. The protein expression of PDL1 is highly correlated with those of elf2alphal and ATF4 in lung cancer. Dis. Markers 2018, 5068701 (2018).

25. Host, K. M., Jacobs, S. R., West, J. A., Zhang, Z., Costantini, L. M., Stopford, C. M. et al. High glucose and hyperglycemic sera from type 2 diabetic patients impair macrophage differentiation by inducing ROS and activating Wnt/beta-catenin and p38 MAPK. Autophagy 15, 652–667 (2019).

26. Granato, M., Santerelli, R., Granato, M., Gonnella, R., Torrisi, M. R., Faggioni, A. et al. EBV reduces autophagy, intracellular ROS and mitochondria to impair monocyte survival and differentiation. Autophagy 15, 652–667 (2019).

27. Granato, M., Gilardini Montani, M. S., Filar, M., Faggioni, A. & Ciron, M. Capsaicin triggers immunogenic PEL cell death, stimulates DCs and reverts PEL-induced immune suppression. Oncoarget 6, 29543–29554 (2015).

28. Gilardini Montani, M. S., Granato, M., Cuomo, L., Valla, S., Di Renzo, L., D’Orazi, G. et al. Elevated glucose and hyperglycemic sera from type 2 diabetic patients impair DC differentiation by inducing ROS and activating Wnt/beta-catenin and p38 MAPK. Biochim Biophys. Acta 1862, 805–813 (2016).

29. Granato, M., Gilardini Montani, M. S., Romeo, M. A., Santerelli, R., Gonnella, R., D’Orazi, G. et al. Metformin triggers apoptosis in PEL cells and alters bortezomib-induced unfolded protein response increasing its cytotoxicity and inhibiting KSHV lytic cycle activation. Cell Signal 40, 239–247 (2017).

30. Jaguin, M., Houlbert, N., Fardel, O. & Lecureur, V. Polarization profiles of human M-CSF-generated macrophages and comparison of M1-markers in classically activated macrophages from GM-CSF and M-CSF origin. Cell Immunol. 281, 51–61 (2013).

31. Carmeliet, P. VEGF as a key mediator of angiogenesis in cancer. Oncology 69 (Suppl. 3), 4–10 (2005).

32. Zheng, T., Ma, G., Tang, M., Li, Z., Xu, R. IL-8 secreted from M2 macrophages promoted prostate tumorigenesis via STAT3/MALAT1 pathway. Int J Mol Sci. https://doi.org/10.3390/ijms20010098 (2018).

33. Samaniego, F., Young, D., Grimes, C., Prospero, V., Christofidou-Solomidou, M., DeLisser, H. M. et al. Vascular endothelial growth factor and Kaposi’s sarcoma cells in human skin grafts. Cell Growth Differ. 13, 387–395 (2002).

34. Mossood, R., Cai, J., Tulpule, A., Zheng, T., Hamilton, A., Sharma, S. et al. Interleukin 8 is an autocrine growth factor and a surrogate marker for Kaposi’s sarcoma. Clin. Cancer Res. 7, 2693–2702 (2001).

35. Darwin, L., Coma, G., Pena, R., Bellido, R., Blanco, E. J., Este, J. A. et al. Secretion of interferon-gamma by human macrophages demonstrated at the single-cell level after co-stimulation with interleukin (IL)-12 plus IL-18. Immunology 126, 386–393 (2009).

36. Wu, X., Lahiri, A., Haines, G. K. 3rd, Flavell, R. A. & Abraham, C. NOD2 regulates CXCR3-dependent CD8+ T cell accumulation in intestinal tissues with acute injury. J. Immunol. 192, 3409–3418 (2014).

37. Wang, L., Wakisaka, N., Tomlinson, C. C., DeWire, S. M., Krall, S., Pagano, J. S. et al. The Kaposi’s sarcoma-associated herpesvirus (KSHV/HHV-8) K1 protein induces expression of angiogenic and invasion factors. Cancer Res. 64, 2774–2781 (2004).

38. Gasperini, P., Espigol-Frigole, G., McCormick, P. J., Salvucci, O., Maric, D., Uldrick, T. S. et al. Kaposi sarcoma herpesvirus promotes endothelial-to-mesenchymal transition through Notch-dependent signaling. Cancer Res 72, 1157–1169 (2012).

39. Oh, J., Rieck, A. E., Weng, S., Petty, M., Kim, D., Colonna, M. et al. Endoplasmic reticulum stress controls M2 macrophage differentiation and foam cell formation. J. Biol. Chem. 287, 11629–11641 (2012).

40. Soto-Pantoja, D. R., Wilson, A. S., Clear, K. Y., Westwood, B., Triozzi, P. L. & Cook, K. L. Unfolded protein response signaling impacts macrophage polarity to modulate breast cancer cell clearance and melanoma immune checkpoint therapy responsiveness. Oncoarget 8, 80545–80559 (2017).

41. Cook, K. L., Soto-Pantoja, D. R., Clarke, P. A., Cruz, M. I., Zwart, A., Warni, A. et al. Endoplasmic reticulum stress response can modulate drug sensitivity and antitumor immunity in breast cancer. Cancer Res. 76, 5657–5670 (2016).

42. Nomura, M., Liu, J., Rovira, I. I., Gonzalez-Hurtado, E., Lee, J., Wolfgang, M. J. et al. Fatty acid oxidation in macrophage polarization. Nat. Immunol. 17, 216–217 (2016).

43. Polizzotto, M. N., Uldrick, T. S., Wang, V., Alem, K., Wyvill, K. M., Marshall, V. et al. Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castlemann disease. Blood 122, 4189–4198 (2013).

44. Nagai, K., Ochi, T., Fujiiwa, H., An, J., Shirakata, T., Mineno, J. et al. Aurora kinase A-specific T-cell receptor gene transfer redirects T lymphocytes to display effective antileukemia reactivity. Blood 119, 368–376 (2012).

45. Su, Y. L., Banerjee, S., White, S. V., Kortylewski, M. STAT3 in tumor-associated myeloid cells: multitasking to disrupt immunity. Int. J. Mol. Sci. https://doi.org/10.3390/ijms19061803 (2018).

46. Johnson, D. E., O’Keefe, R. A. & Grandis, J. R. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat. Rev. Clin. Oncol. 15, 234–248 (2018).

47. Liu, Y., Shao, M., Wu, Y., Yan, C., Jiang, S., Liu, J. et al. Role for the endoplasmic reticulum stress sensor Ire1alpha in liver regenerative responses. J. Hepatol. 62, 590–598 (2015).

48. Gilardini Montani, M. S., Santerelli, R., Falcinelli, L., Gonnella, R., Granato, M., Di Renzo, L. et al. EBV up-regulates PD-L1 on the surface of primary monocytes by increasing ROS and activating TLR signaling and STAT3. J. Leukoc. Biol. 104, 821–832 (2018).

49. Salmaninejad, A., Zamani, M. R., Shabgah, A. G., Hosseini, S., Mollaeim, F., Hosseini, N. et al. Behcet’s disease: an immunogenetic perspective. J. Cell. Physiol. 254, 8055–8074 (2019).

50. Porcheray, F., Viaud, S., Rimanoli, A. C., Leone, C., Samah, B., Dureudre-Bosquet, N. et al. Macrophage activation switching: an asset for the resolution of inflammation. J. Exp. Immunol. 142, 481–489 (2005).